NCT02965573 - A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 30, 2016

Primary Completion Date

October 20, 2017

Study Completion Date

October 20, 2017

Conditions

Myasthenia Gravis

Interventions

BIOLOGICAL

ARGX-113

DRUG

Placebo

Trial Locations (19)

Investigator Site 19, Irvine

Investigator Site 17, Los Angeles

Investigator Site 15, Tampa

Investigator Site 16, Indianapolis

Investigator Site 14, Chapel Hill

Investigator Site 18, Dublin

Investigator Site 2, Ghent

Investigator Site 1, Leuven

Investigator Site 4, Montreal

Investigator Site 3, Toronto

Investigator Site 7, Bergamo

Investigator Site 6, Milan

Investigator Site 5, Roma

Investigator Site 8, Leiden

Investigator Site 10, Gdansk

Investigator Site 9, Krakow

Investigator Site 12, Barcelona

Investigator Site 11, Madrid

Investigator Site 13, Solna